Tables
- TABLE 1
Clinical trials investigating oligometastatic disease
Identifier Title Description Allocation Status NCT03965468 Immunotherapy, chemotherapy, radiotherapy and surgery for synchronous oligo-metastatic NSCLC Immunotherapy, chemotherapy plus stereotactic radiotherapy to synchronous oligo-metastases followed by definitive surgery or radiotherapy to primary NSCLC Recruiting NCT03827577 OMEGA, local ablative therapy in oligometastatic NSCLC Resection of primary NSCLC plus local ablative therapy to all metastases versus standard-of-care chemotherapy Randomised Recruiting NCT03275597 Phase Ib study of stereotactic body radiotherapy (SBRT) in oligometastatic non-small lung cancer (NSCLC) with dual immune checkpoint inhibition SBRT followed by combined durvalumab and tremelimumab Recruiting NCT03119519 Local non-salvage radiotherapy for synchronous oligometastatic non-small-cell lung cancer Chemotherapy plus local definitive radiotherapy to primary and oligo-metastases versus standard-of-care chemo-/targeted-therapy Randomised Recruiting NCT02975609 Phase II trial of SBRT compared with conventional radiotherapy for oligometastatic non-small cell lung cancer Chemotherapy plus SBRT versus chemotherapy plus conventional fractionated radiotherapy to primary and all metastatic sites Randomised Not yet recruiting NCT02417662 Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer Patients will be randomised to receive either standard chemotherapy treatment alone or standard treatment with conventional radiotherapy and SABR Randomised Recruiting NCT02054819 Treating NSCLC minimal stage IV with curative intent Platinum-based chemotherapy with concurrent radiation therapy to the primary tumour and identified mediastinal lymph nodal metastatic drainage. Local curative radiation will then target the oligometastatic tumour sites Terminated (low accrual) NCT01185639 Stereotactic body radiation therapy (SBRT) in metastatic non-small cell lung cancer Chemotherapy followed by local ablative radiotherapy to all metastatic lesions Completed NSCLC: nonsmall cell lung cancer; SBRT: stereotactic body radiotherapy; SABR: stereotactic ablative radiotherapy.
Vol 30 Issue 159
Table of Contents
How to handle oligometastatic disease in nonsmall cell lung cancer
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Definition of the oligmetastatic situation and prognostic implications
- Ablative techniques in the treatment of oligometastases
- Lung oligometastases
- Brain metastases
- Adrenal metastases
- Bone metastases
- Other extrathoracic locations
- The role of systemic treatment of oligometastatic disease
- Current patient selection and prognostic factors
- Ongoing clinical trials
- Conclusion and future directions
- Footnotes
- References
- Figures & Data
- Info & Metrics